Hypoxia-mimetic by CoCl2 Increases SLC7A5 Expression in Breast Cancer Cells in Vitro
Overview
General Medicine
Affiliations
Objective: Increased expression of the amino acid transporter solute Carrier Family 7 Member 5 (SLC7A5) has been observed in neoplastic cells during hypoxic conditions in vitro, indicating an adaptation for cell survival. To further explore this, we evaluated hypoxia-mimetic by CoCl2 as a model for hypoxia in breast cancer cell lines and the effect on SLC257A5 expression. Four different breast cancer cell lines (MCF7, T-47D, BT-474 and ZR-75-1) were exposed to 100 µM CoCl for 48 h. Subsequently, cell viability, gene- and protein expression analyses were performed.
Results: The gene expression of VEGF, a marker of hypoxia, was significantly elevated in all four cell lines compared to the control (p < 0.0001), indicating that CoCl exposure generates a hypoxic response. Moreover, CoCl exposure significantly upregulated SLC7A5 gene expression in T-47D (p < 0.001), BT-474 (p < 0.0001) and ZR-75-1 (p < 0.0001) cells, as compared to vehicle control. Immunofluorescence staining showed increased SLC7A5 protein expression in MCF7, T-47D and BT-474 cells compared to vehicle control. This report suggests that hypoxia-mimetic by CoCl can be used as a simple model for inducing hypoxia in breast cancer cell lines and in fact influence SLC7A5 gene and protein expression in vitro.
Nobiletin: a potential erythropoietin receptor activator protects renal cells against hypoxia.
Liu N, Sun Y, Liu J, Zhang Y, Yi X, Yan W Apoptosis. 2025; .
PMID: 39755823 DOI: 10.1007/s10495-024-02067-9.
Identification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis.
Yoon M, Chun H, Lee H, Seo W, Lee J, Yoon J Cancer Med. 2024; 13(23):e70460.
PMID: 39628390 PMC: 11615507. DOI: 10.1002/cam4.70460.